659 research outputs found
Reliability and Efficiency of the CAPRI-3 Metastatic Prostate Cancer Registry Driven by Artificial Intelligence
Background: Manual data collection is still the gold standard for disease-specific patient registries. However, CAPRI-3 uses text mining (an artificial intelligence (AI) technology) for patient identification and data collection. The aim of this study is to demonstrate the reliability and efficiency of this AI-driven approach. Methods: CAPRI-3 is an observational retrospective multicenter cohort registry on metastatic prostate cancer. We tested the patient-identification algorithm and automated data extraction through manual validation of the same patients in two pilots in 2019 and 2022. Results: Pilot one identified 2030 patients and pilot two 9464 patients. The negative predictive value of the algorithm was maximized to prevent false exclusions and reached 94.8%. The completeness and accuracy of the automated data extraction were 92.3% or higher, except for date fields and inaccessible data (images/pdf) (10–88.9%). Additional manual quality control took over 3 h less time per patient than the original fully manual CAPRI registry (105 vs. 300 min). Conclusions: The CAPRI-3 patient-identification algorithm is a sound replacement for excluding ineligible candidates. The AI-driven data extraction is largely accurate and complete, but manual quality control is needed for less reliable and inaccessible data. Overall, the AI-driven approach of the CAPRI-3 registry is reliable and timesaving.</p
Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
Objective: To assess the cost effectiveness of cetuximab in third-line treatment of patients with KRAS wild-type
(wt) metastatic colorectal cancer (mCRC) in routine clinical practice compared with best supportive care (BSC).
Methods: Patients (n = 287) with KRAS wt mCRC treated with cetuximab or BSC in eight hospitals in
the Netherlands between 2009 and 2012 were included in our real-world study. Outcome measures were costs per
life-year (LY) and costs per quality-adjusted LY (QALY) gained. A Markov model was developed, and a time horizon
of four years was applied. Outcomes were calculated from Kaplan-Meier survival curves from patient-level data and
literature. Direct medical costs were estimated in all centers (2013 values), and incremental cost-effectiveness ratios
(ICERs) were calculated. Results were discounted, and a probabilistic sensitivity analysis was performed.
Results: Administration of cetuximab in third-line treatment of mCRC resulted in a gain of 0.29 LYs and 0.25 QALYs
compared with BSC. In the four-year study period, average discounted healthcare costs were €36,637 in the
cetuximab group vs. €3648 in the BSC group. The discounted ICERs of cetuximab vs. BSC in the real-world setting
were €114,907and €133,527 per LY and QALY gained, respectively.
Conclusions: Results of this cost-effectiveness analysis showed that third-line treatment with cetuximab for patients
with KRAS (exon 2) wt mCRC offered clinical benefits at additional cost. The real-world ICERs were in line with those
of previously published cetuximab and panitumumab cost-utility models
Early markers of atrial fibrillation recurrence after pulmonary vein isolation
Background: Postprocedural atrial extrasystole (AES) frequency predicts atrial fibrillation (AF) recurrence after pulmonary vein isolation (PVI) in patients with paroxysmal AF. However, the predictive value of preprocedural AES frequency is unknown. We investigate whether preprocedural AES frequency is a feasible marker to predict (timing of) AF recurrence after PVI. Methods: Patients (N = 684) with paroxysmal or persistent AF undergoing first-time PVI were evaluated for (a) the frequency of AES/day on Holter recordings without AF prior to PVI, (b) AF episodes during the 90 days blanking period, and (c) AF recurrences afterward. The correlation between AES/day and both development and timing of AF recurrences was tested. Results: Preprocedural AES/day was similar in patients with paroxysmal (66 [20-295] AES/day) and persistent AF (115 [12-248] AES/day, P =.915). During the blanking period, 302 (44.2%) patients showed AF episodes. AF recurred in 379 (55.4%) patients at 203 (105-400) days after PVI. AF recurred more frequently in patients with persistent (N = 104 [69.3%]) than in patients with paroxysmal AF (N = 275 [51.5%], P <.001). Frequency of AES prior to PVI was not correlated with development (P =.203) or timing (P =.478) of AF recurrences. AF recurrences occurred both more frequently (P <.001) and earlier (P <.000) in patients with AF during the blanking period. Conclusion: AES/day prior to PVI is not correlated with (timing of) AF during the blanking period or AF recurrences, and is therefore not a feasible marker for AF recurrences in patients with PAF. AF during the blanking period is correlated with AF recurrence
Effects of hypoxia on buoyancy control and the development of lordosis in physostomous and physoclistous fish species
Solid state NMR/Biophysical Organic Chemistr
Casimir Energies for 6D Supergravities Compactified on T_2/Z_N with Wilson Lines
We compute (as functions of the shape and Wilson-line moduli) the one-loop
Casimir energy induced by higher-dimensional supergravities compactified from
6D to 4D on 2-tori, and on some of their Z_N orbifolds. Detailed calculations
are given for a 6D scalar field having an arbitrary 6D mass m, and we show how
to extend these results to higher-spin fields for supersymmetric 6D theories.
Particular attention is paid to regularization issues and to the identification
of the divergences of the potential, as well as the dependence of the result on
m, including limits for which m^2 A> 1 where A is the volume of
the internal 2 dimensions. Our calculation extends those in the literature to
very general boundary conditions for fields about the various cycles of these
geometries. The results have potential applications towards Supersymmetric
Large Extra Dimensions (SLED) as a theory of the Dark Energy. First, they
provide an explicit calculation within which to follow the dependence of the
result on the mass of the bulk states which travel within the loop, and for
heavy masses these results bear out the more general analysis of the
UV-sensitivity obtained using heat-kernel methods. Second, because the
potentials we find describe the dynamics of the classical flat directions of
these compactifications, within SLED they would describe the present-day
dynamics of the Dark Energy.Comment: 40 pages, 7 figure
Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
__Abstract__
For patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), chemotherapy can prolong life and alleviate symptoms. However, expected gains may be small, not necessarily outweighing considerable toxicity and high costs. Treatment choice is to a large extent dependent on preferences of doctors and patients and data on these choices are scarce. The purpose of this study is to obtain real-world information on palliative systemic treatment and costs of R/M SCCHN in the Netherlands. In six Dutch head and neck treatment centers, data were collected on patient and tumor characteristics, treatment patterns, disease progression, survival, adverse events, and resource use for R/M SCCHN, between 2006 and 2013. 125 (14 %) out of 893 R/M SCCHN patients received palliative, non-trial first-line systemic treatment, mainly platinum + 5FU + cetuximab (32 %), other platinum-based combination therapy (13 %), methotrexate monotherapy (27 %) and capecitabine monotherapy (14 %). Median progression-free survival and overall survival were 3.4 and 6.0 months, respectively. 34 (27 %) patients experienced severe adverse events. Mean total hospital costs ranged from €10,075 (±€9,891) (methotrexate monotherapy) to €39,459 (±€21,149) (platinum + 5FU + cetuximab). Primary cost drivers were hospital stays and anticancer drug treatments. Major health care utilization and costs are involved in systemically treating R/M SCCHN patients with a limited survival
Functional decline after surgery in older patients with head and neck cancer
Introduction: In addition to classical endpoints such as survival and complication rates, other outcomes such as quality of life and functional status are increasingly recognized as important endpoints, especially for elderly patients. However, little is known about the long-term effect of surgery with regard to these other outcomes. Our aim is to investigate the functional status and self-reported health status of patients > 70 years one year after surgery for head and neck cancer. Methods: We present one-year follow-up data of patients > 70 year who underwent surgery for HNC. During an interview by telephone, functional status was evaluated by using the Katz-15 Index of Independence questionnaire including six items covering basic Activities of Daily Living (ADL) and nine items covering Instrumental Activities of Daily Living (IADL). Measurements were compared with those obtained preoperatively. Results: In total, 126 patients were included and eventually we collected follow-up data of 68 patients. There was a statistically significant decrease in functional status on the total Katz-15 and on the IADL questionnaire scores one year after surgery (mean 1.34 versus 2.42, p -value 0.00 and mean 1.21 versus 1.94, p- value 0.00). There was no significant change concerning ADL dependence ( p -value 0.18) and cognitive status ( p -value 0.11). The self-reported health status improved postoperatively, although not statistically significantly so (mean 67.36 versus 71.25, p -value 0.12). Conclusion: Approximately-one year after surgery for HNC, there is a significant decline in functional status indicating a higher level of dependency.Pathophysiology, epidemiology and therapy of agein
ICTV Virus Taxonomy Profile:Coronaviridae 2023
The family Coronaviridae includes viruses with positive-sense RNA genomes of 22-36 kb that are expressed through a nested set of 3' co-terminal subgenomic mRNAs. Members of the subfamily Orthocoronavirinae are characterized by 80-160 nm diameter, enveloped virions with spike projections. The orthocoronaviruses, severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome-related coronavirus are extremely pathogenic for humans and in the last two decades have been responsible for the SARS and MERS epidemics. Another orthocoronavirus, severe acute respiratory syndrome coronavirus 2, was responsible for the recent global COVID-19 pandemic. This is a summary of the International Committee on Taxonomy of Viruses (ICTV) Report on the family Coronaviridae which is available at www.ictv.global/report/coronaviridae.</p
Balancing of Histone H3K4 Methylation States by the Kdm5c/SMCX Histone Demethylase Modulates Promoter and Enhancer Function
SummaryThe functional organization of eukaryotic genomes correlates with specific patterns of histone methylations. Regulatory regions in genomes such as enhancers and promoters differ in their extent of methylation of histone H3 at lysine-4 (H3K4), but it is largely unknown how the different methylation states are specified and controlled. Here, we show that the Kdm5c/Jarid1c/SMCX member of the Kdm5 family of H3K4 demethylases can be recruited to both enhancer and promoter elements in mouse embryonic stem cells and in neuronal progenitor cells. Knockdown of Kdm5c deregulates transcription via local increases in H3K4me3. Our data indicate that by restricting H3K4me3 modification at core promoters, Kdm5c dampens transcription, but at enhancers Kdm5c stimulates their activity. Remarkably, an impaired enhancer function activates the intrinsic promoter activity of Kdm5c-bound distal elements. Our results demonstrate that the Kdm5c demethylase plays a crucial and dynamic role in the functional discrimination between enhancers and core promoters
- …